Abstract:Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with relapsed/refractory cHL over camrelizumab alone. Methods This extended follow-up of an ongoing randomized phase II trial analyzed PFS among patients enrolled from January 2017 through July 2018. Sixty-one patients with relapsed/refractory cHL who were clinically naïve to PD-1 blockade and had received ≥2 previous therapies were randomized 1:2 to receive either camrelizumab (200 mg) monotherapy or camrelizumab (200 mg, day 8) combined with decitabine (10 mg/day, days 1–5) every 3 weeks. Results With a median follow-up of 34.5 months, complete remission was 79% (95% CI 63% to 90%) in the decitabine-plus-camrelizumab group versus 32% (95% CI 13% to 57%) in the camrelizumab group (p=0.001). Median duration of response was not reached in the decitabine-plus-camrelizumab group, with an estimated 63% (95% CI 46% to 75%) of patients maintaining a response at 24 months. Median PFS with decitabine-plus-camrelizumab therapy was 35.0 months (95% CI not reached) and 15.5 months (95% CI 8.4 to 22.7 months) with camrelizumab monotherapy (HR, 0.46; 95% CI 0.21 to 1.01; p=0.02). Female gender, lower tumor burden, and fewer previous therapies were favorable prognostic factors for durable remission with camrelizumab monotherapy. The PFS benefits of decitabine-plus-camrelizumab versus camrelizumab were observed in most subgroups, especially in patients with relative larger tumor burdens and those treated with ≥3 prior therapies. After decitabine-plus-camrelizumab treatment, the percentage increase of circulating peripheral central memory T-cells correlated with both improved clinical response and PFS, suggesting a putative biomarker of decitabine-plus-camrelizumab therapy for cHL. Conclusions Decitabine-plus-camrelizumab results in longer PFS compared with camrelizumab alone in patients with relapsed/refractory cHL. Trial registration numbers NCT02961101 and NCT03250962 .

Supplementary Fig 4 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Fig 5 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Epigenetic Agents Plus Anti-Pd-1 Reshapes Tumor Microenvironment and Restores Antitumor Efficacy in Hodgkin Lymphoma

Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Supplementary Fig 4 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Fig 5 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Epigenetic Agents Plus Anti-Pd-1 Reshapes Tumor Microenvironment and Restores Antitumor Efficacy in Hodgkin Lymphoma

Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Supplementary Figure 3 from Margin-Infiltrating CD20&lt;sup&gt;+&lt;/sup&gt; B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Figure 4 from Margin-Infiltrating CD20&lt;sup&gt;+&lt;/sup&gt; B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma